Novartis AG
NVSEF
$106.50
-$3.64-3.30%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.96% | -11.63% | -1.76% | 20.76% | -68.30% |
| Total Depreciation and Amortization | 596.97% | -85.80% | 4.12% | -3.46% | 176.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -38.98% | 31.86% | 97.34% | -25.23% | 120.47% |
| Change in Net Operating Assets | -686.27% | -130.95% | 1,748.00% | 97.86% | -216.42% |
| Cash from Operations | -13.07% | -33.30% | 28.94% | 115.23% | -11.07% |
| Capital Expenditure | 54.48% | -73.83% | -23.46% | -14.54% | 44.09% |
| Sale of Property, Plant, and Equipment | -78.72% | 4,600.00% | -97.30% | 3,600.00% | -99.39% |
| Cash Acquisitions | -- | -634.48% | 98.24% | -1,266.39% | -3,916.67% |
| Divestitures | -102.44% | 2,242.86% | 126.92% | 31.58% | -1,800.00% |
| Other Investing Activities | 125.58% | -75,233.33% | -100.90% | 185.03% | 73.91% |
| Cash from Investing | 110.88% | -710.96% | 88.34% | -256.73% | 48.92% |
| Total Debt Issued | 2,416.67% | -100.65% | 20.64% | 149.34% | 123.44% |
| Total Debt Repaid | -1,215.85% | 92.93% | 47.49% | -3,197.01% | -204.69% |
| Issuance of Common Stock | -- | -100.00% | -80.00% | -- | -- |
| Repurchase of Common Stock | 1.67% | 3.22% | -76.61% | -47.04% | 12.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | 53.58% | -- |
| Other Financing Activities | 117.97% | -197.67% | -72.00% | -127.27% | -128.21% |
| Cash from Financing | -185.31% | -684.29% | 88.06% | 38.03% | -750.74% |
| Foreign Exchange rate Adjustments | 157.32% | -278.41% | 617.65% | 73.02% | -178.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -104.33% | -137.68% | 464.37% | 60.09% | -497.17% |